Fintel reports that on November 5, 2024, William Blair downgraded their outlook for Marqeta (NasdaqGS:MQ) from Outperform to ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Fly fishing enthusiasts seeking a once-in-a-lifetime experience in untouched wilderness will soon have a new destination: the ...

Equities researchers at William Blair raised their Q4 2024 EPS estimates for shares of Cheesecake Factory in a research note ...

However, for William “Will” Blair, it is his passion. Known for his relentless pursuit of untouched rivers and wilderness settings, Will has built a career and a lifestyle centered around ...

Investment analysts at William Blair increased their FY2024 earnings per share (EPS) estimates for Lennox International in a ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Outperform to Market Perform. There are 1,150 funds or institutions ...

Photo courtesy of Republic Services Inc. Chicago-based equities advisory firm William Blair has appointed equity research analyst Trevor Romeo to initiate coverage of three companies in the solid ...

ResMed reports Q1 2025 adjusted EPS of $2.20, up 34%, beating estimates. Revenue reached $1.22 billion, up 11%, driven by demand growth.